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PEGylated polylysine dendrimers have demonstrated potential as inhalable drug delivery systems 
that can improve the treatment of lung cancers. Their treatment potential may be enhanced by 
developing constructs that display prolonged lung retention, together with good systemic 
absorption, the capacity to passively target lung tumours from the blood and highly selective, yet 
rapid liberation in the tumour microenvironment. This study sought to characterise how the nature 
of cathepsin B cleavable peptide linkers, used to conjugate doxorubicin to a PEGylated (PEG570) 
G4 polylysine dendrimer, affect drug liberation kinetics and intravenous and pulmonary 
pharmacokinetics in rats. The construct bearing a self-emolative diglycolic acid-V-Citrulline linker 
exhibited faster doxorubicin release kinetics compared to constructs bearing self emolative 
diglycolic acid-GLFG, or non-self emolative glutaric acid-GLFG linkers. The V-Citrulline construct 
exhibited slower plasma clearance, but faster absorption from the lungs than a GLFG construct, 
although mucociliary clearance and urinary elimination were unchanged. Doxorubicin-conjugation 
enhanced localisation in the bronchoalveolar lavage fluid compared to lung tissue, suggesting that 
projection of doxorubicin from the dendrimer surface reduced tissue uptake. These data show that 
the linker chemistry employed to conjugate drugs to PEGylated carriers can affect drug release 
profiles and systemic and lung disposition.  
 
 
 
 
 
 
 
 
 
 
 
Keywords: pharmacokinetics, lung clearance, cathepsin B, pulmonary, doxorubicin, dendrimer. 
 
 
Abbreviations: BALF, bronchoalveolar lavage fluid; DGA, diglycolic acid; VCit, Valine-
Citrulline; Dox, doxorubicin; Glu-GLFG; glutaric acid-glycine-leucine-phenylalanine-glycine; 
GFLG, glycine-leucine-phenylalanine-glycine; DGA, diglycolic acid; PAB, para-amino benzoic 
acid; G, generation. 
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Previous work has shown that inhaled PEGylated polylysine dendrimers provide an excellent 
platform for the delivery of drugs to the lungs, and for subsequent systemic exposure1, 2. They 
exhibit tuneable pharmacokinetic properties that can be tailored to promote prolonged lung 
retention, systemic access or both2. For example, pulmonary administration of a 56 kDa PEGylated 
G5 dendrimer conjugated with the chemotherapeutic drug doxorubicin (Dox) via an acid labile 
hydrazone linker, dramatically improved the activity of doxorubicin against lung metastases in rats 
when compared to the intravenous administration of drug alone1. This construct was also well 
tolerated by rats after administration of up to 80 mg of dendrimer to the lungs. In contrast, the 
pulmonary administration of doxorubicin alone induced significant lung-related toxicity after a 
single dose. In spite of these encouraging results, some evidence of lung necrosis was apparent in 
~50% of animals administered the Dox-dendrimer as a result of non-specific Dox liberation. 
To enhance the therapeutic utility of this system, we sought here to explore the potential of 
conjugation chemistries to reduce the degree of non-tumour specific drug release, yet allow rapid 
drug liberation in tumours, and also to try to identify constructs that exhibit prolonged lung 
exposure, good systemic absorption and enhanced plasma exposure. Thus, we aimed to provide an 
inhalable delivery system with the potential to be retained in the lungs resulting in specific drug 
liberation on the ‘air side’ of lung tumours, together with absorption from the lungs and passive 
targeting from the ‘blood side’ of tumours via enhanced permeation and retention to enhance drug 
exposure to the whole tumour. In this way, pulmonary and systemic side effects are expected to be 
reduced (compared to drug alone) by minimising the exposure of non-cancerous tissues to free 
drug. 
A series of G4 dendrimers conjugated with PEG570 and doxorubicin (20-30 kDa in size) were 
synthesised based on previous data showing that this scaffold construction offers both prolonged 
systemic exposure and good lung absorption2, 3 (see figure in supporting information). Three 
peptide-based drug linkers that are specifically cleavable by cathepsin B were used to conjugate 
doxorubicin to this dendrimer scaffold: a pentapeptide (Glu-GLFG4) that results in the liberation of 
both peptide-modified and unmodified doxorubicin, and two self-emolative systems (diglycolic 
acid-GLFG-para-amino benzoic acid4 and diglycolic acid-Valine-Citrulline (VCit)-para-amino 
benzoic acid5) that facilitate the liberation of unmodified doxorubicin. Cathepsin B-cleavable 
peptides were used since the extracellular and lysosomal expression of this enzyme is highly 
upregulated by cancer cells, particularly those at the invasive front of a tumour, but is constitutively 
expressed at low levels in normal tissue6-8.  
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Materials and dendrimers 
Scintillation vials, Soluene tissue solubiliser and IRGASafe scintillant were from Perkin Elmer 
(Vic, Australia). Cell culture media and supplements were from Invitrogen (Vic Australia). 
 
Dendrimers were synthesised and characterised as described previously9, with modification (see 
supplementary information for synthetic details). 3H-lysine was incorporated into the penultimate 
generation to enable pharmacokinetic characterisation of the dendrimer construct. The specific 
activity of the dendrimers was determined via scintillation counting10.  
 
Doxorubicin release kinetics and in vitro cytotoxicity 
The kinetics of Dox release in the presence of cathepsin B was initially investigated by incubating 1 
ug/ml Dox equivalents (approx. 5 ug/ml dendrimer) with 1 IU/ml cathepsin B (Sigma, MO, USA) 
in 0.1 M acetate buffer containing EDTA (0.01 M) and glutathione (0.05 M) at 37°C for 2 days. 
Dox release from G4PEG570-DGA-VCit was also examined in the absence of cathepsin to confirm 
enzyme-specific liberation. Aliquots of the reaction mixture were collected at various time points 
and assayed via fluorescence HPLC for free Dox11. 
 
The in vitro growth inhibitory effects of the Dox dendrimers, as well as a solution formulation of 
Dox and a non-Dox conjugated control dendrimer were evaluated using an MTT assay in 96 well 
microplates against human mammary MCF7 cells and human lung A549 cells over 3 days and a 
concentration range of 0.1 nM to 500 uM as previously described9. Cells were grown in RPMI 
media supplemented with 10% FBS and 1% glutamax and maintained in a humidified environment 
at 37°C and 5% CO2.  
 
Intravenous and pulmonary pharmacokinetics in rats 
Male Sprague Dawley rats (8 weeks) were obtained from the Monash Animal Platform (Monash 
University, Vic, Australia) and housed at ambient temperature on a 12 h light/dark cycle. Water and 
food were freely available with the exception of overnight after surgery and for up to 8h after 
dosing. All experimentation involving animals was approved by the institutional animal ethics 
committee.  
 
The right carotid artery and jugular vein of rats was cannulated with 0.96 mm external / 0.58 mm 
internal diameter polyethylene catheters to facilitate IV dosing and serial blood sampling 
respectively under isoflurane anaesthesia10. After overnight recovery in individual metabolism 
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cages, rats were delivered a dendrimer dose of 5 mg/kg (in 1 ml saline) IV via the jugular vein 
cannula, or via intratracheal instillation into the lungs (in 150 ul saline) as previously described2, 10. 
Urine and feces were collected and assayed via scintillation counting during this time as previously 
described10. Serial blood samples (200 ul) were collected from the carotid artery cannula over 5 
days, after which time rats were terminated and bronchoalveolar lavage fluid (BALF) and major 
organs collected for biodistribution analysis. A separate cohort of rats (n=3 per dendrimer) were 
dosed via the lungs with dendrimer and euthanised 1 or 9 days later and BALF and lung tissue 
collected to evaluate the time course of lung clearance.  
 
The tritium content of plasma, urine, total feces, bronchoalveolar lavage fluid (BALF) and major 
organs (lungs, liver, kidneys, spleen, heart) was quantified via scintillation counting as previously 
described10. Non-compartmental pharmacokinetics were evaluated based on the specific 
radioactivity of dendrimers quantified in the plasma as previously described12. 
 
Size exclusion chromatography 
Plasma, BALF and urine samples (100-200 ul; where sample radioactivity was sufficiently high) 
were injected onto a Superdex 200 column (GE Healthcare, Sweden) and eluted at a flow rate of 0.5 
ml/min in a mobile phase of 50 mM PBS containing 0.3M NaCl (pH 3.5) to identify 3H species in 
these samples. Fractions were collected at 1 min intervals, mixed with 2 ml IRGASafe and analysed 
on a scintillation counter.  
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Drug release kinetics and in vitro cytotoxicity 
Of the Dox-conjugated dendrimers examined, the drug was most efficiently released from the 
DGA-VCit linker, with nearly 50% Dox released over 2 days (Fig 1) compared to no quantifiable 
release in the absence of cathepsin (<5%, the limit of assay sensitivity; not shown). Approximately 
33% of unmodified Dox was released from the DGA-GLFG linker over 2 days, whilst 26% of Dox 
was released from the non-self emolative Glu-GLFG counterpart, presumably reflecting the 
predominance of cleavage to form FG-modified drug.  
 
The in vitro cytotoxicity of the constructs and doxorubicin alone was then evaluated against human 
lung (A549) and mammary (MCF) adenocarcinoma cells (Fig 1B & C respectively). Despite the 
differences in Dox release kinetics, there were no significant differences in the growth inhibitory 
effects of the three constructs against A549 or MCF7 cells. A non-Dox loaded control dendrimer 
exhibited no growth inhibitory effects over the concentration range examined, confirming that the 
cytotoxicity of the Dox constructs was related to drug liberation. It is possible however, that 
cathepsin release into the media was not high enough over the 3 day incubation period to exemplify 
differences in the sensitivity of the linkers to cleavage by this enzyme in a cell-based system. 
Intravenous pharmacokinetics and biodistribution 
Since the DGA-self emolative systems displayed the best in vitro drug liberation profiles, these 
constructs were then progressed into in vivo studies in rats and their intravenous and pulmonary 
pharmacokinetics evaluated. The dendrimer containing the DGA-VCit linker was cleared ~2 fold 
slower than G4PEG570-DGA-GLFG after IV administration, although terminal half-lives 
(approximately 1.5 days) were similar, indicating reductions in volume of distribution of a similar 
magnitude (Fig 2, Table 1). In contrast, a corresponding fully PEGylated construct (ie non-drug 
conjugated, G4 100% PEG570 conjugated) reported previously, was cleared from plasma ~1.5 to 3 
fold faster, although terminal half-life was similar (supporting information)3. These differences may 
reflect changes in the interaction of dendrimers with membranes and plasma proteins as a result of 
differences in the presentation or orientation of Dox which is extensively protein bound in plasma.  
 
Despite the reduction in total clearance and volume of distribution of G4PEG570-DGA-VCit, ~45% of 
both Dox-dendrimers were eliminated via the urine (Table 1)12 and at the same rate (not shown). 
Although the proportion of urinary elimination was similar to the fully PEGylated dendrimer, 3H-
label from the Dox-dendrimers was eliminated as both intact dendrimer and low MW products of 
polylysine catabolism (supporting information), which was not observed previously for the fully 
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catabolism than the fully PEGylated construct, presumably as a result of the liberation of Dox over 
time and exposure of the polylysine scaffold to proteases12. Organ biodistribution profiles of the 
two dendrimers were also similar, although G4PEG570-DGA-GLFG displayed moderately higher 
organ retention than G4PEG570-DGA-VCit (Fig 3 and supporting information)3. Dox dendrimers also 
displayed more extensive kidney retention after IV administration than the fully PEGylated 
dendrimer, despite displaying similar urinary elimination (supporting information). 
 
Pulmonary pharmacokinetics and biodistribution 
After pulmonary administration of G4PEG570-DGA-GLFG plasma concentrations plateaued over 1 to 
5 days post dose at approx. 1000 ng/ml (Table 1). As a result, absolute bioavailability was not 
determined, although 12% of the dose was bioavailable up to 5 days (based on truncated AUC to 5 
days). G4PEG570-DGA-VCit was absorbed from the lungs with a Tmax of 30 h, and 9% of the dose 
was absorbed as intact dendrimer over 5 days. In this case, a terminal elimination half-life could be 
estimated (possibly due to more extensive urinary elimination after pulmonary administration) and 
therefore absolute bioavailability was calculated to be ~20%. In contrast, previous studies suggest 
that the fully PEGylated counterpart is absorbed faster than the Dox dendrimers examined here 
(Tmax 13 h; Cmax ~2600 ng/ml) and has higher pulmonary bioavailability (up to 30%)2. The 
presentation of Dox on the dendrimer surface therefore appears to slow and potentially limit 
pulmonary absorption. 
 
Despite differences in the absorption profiles after pulmonary administration, lung clearance rates 
and extent of mucociliary elimination from the lungs (10-15%) were similar for both dendrimers 
(Table 1, Fig 3). The Dox dendrimers were also mainly localised in the BALF, whereas the 
previously reported fully PEGylated dendrimer was predominant localisation in lung tissue3.  
 
Conclusion 
In summary, the results suggest that the presentation of Dox on the surface of a short PEG (570 
Da)-conjugated G4 dendrimer prolongs retention in the lung mucus, and slows absorption from the 
lungs and plasma clearance compared to a fully PEGylated dendrimer. This is in contrast to larger 
(G5) dendrimers with higher PEG loading (PEG1100) which appear to better mask the drug in 
vivo1. The data further suggest that the dendrimer with the shortest G4PEG570-DGA-VCit self 
emolative linker displays the most optimal balance between prolonged lung and plasma exposure, 
together with absorption from the lungs after pulmonary administration, whilst also providing 
maximal rates of drug release in the presence of cathepsin B.  
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Figure 1. Doxorubicin release kinetics and in vitro cytotoxicity. Panel A: Kinetics of Dox release 
from each dendrimer in the presence of cathepsin B. Panel B: Cytotoxicity of the three dendrimers 
against human lung carcinoma A549 cells, and Panel C: human mammary MCF7 cells. Symbols 
represent: () G4PEG570-DGAVCit; () G4PEG570-Glu-GLFG; () G4PEG570-DGAGLFG; () Dox; 
() Blank dendrimer. Data represent mean ± s.d. (n=3). 
 
Figure 2. Plasma concentration-time profiles for (A) G4PEG570-DGA-GLFG, and (B) G4PEG570-
DGA-VCit after intravenous and pulmonary administration to rats at 5 mg/kg. Mean ± s.d. (n=3-4). 
 
Figure 3. Biodistribution of dendrimers and time course for dendrimer clearance from the lungs 
after pulmonary administration. Organ biodistribution of (A) 3H-G4PEG570-DGA-GLFG, and (B) 3H-
G4PEG570-DGA-VCit was determined 5 days after IV or pulmonary administration to rats. The time 
course for the lung clearance of (C) G4PEG570-DGA-GLFG and (D) G4PEG570-DGA-VCit was 
evaluated separately in BALF and lung tissue over 9 days after pulmonary administration. Mean ± 
s.d. (n=3-4).  
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Table 1. Pharmacokinetic parameters of 3H-dendrimers after intravenous and pulmonary 
administration to rats at 5 mg/kg. Mean ± s.d. (n=3-4). *p<0.05 cf. DGA-GLFG. 
  G4PEG570-DGAGLFG G4PEG570-DGAVCit 
Parameter Units  IV Pulmonary IV Pulmonary 
t½ h 33 ± 7 ND 36 ± 3 102 ± 60 
AUC0-∞ µg/ml.h 686 ± 100 ND 1526 ± 119* 254 ± 95 
AUC0-5d µg/ml.h - 84 ± 21 - 131± 77 
Vc ml 14 ± 2 - 12 ± 1 - 
VDβ ml 87 ± 25 - 43 ± 6* - 
Cl ml/h 1.8 ± 0.4 - 0.8 ± 0.1* - 
Tmax h - 24 to 120 - 30 ± 0 
Cmax ng/ml - 999 ± 286 - 1639 ± 628 
F (to 5d) % - 12 ± 3 - 9 ± 5 
Urine % 48 ± 5 8 ± 3 43 ± 10 16 ± 6 
Feces % ND 15 ± 4 ND 10 ± 9 
ND: not determined. BQ: below quantification. 
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